Document Detail


Tissue renin-angiotensin system: a site of drug action?
MedLine Citation:
PMID:  9131246     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In this review, we present background material that provides partial support for a tissue renin-angiotensin system (RAS). Evidence for the existence of this system relied in part on the use of drugs, which has entailed using low doses or concentrations of angiotensin-converting enzyme inhibitors, renin inhibitors, and angiotensin antagonists to block the RAS in vascular beds and in isolated arteries or organs. Other evidence for a tissue RAS has depended upon measurements of the components of the system, i.e. enzymes, substrates, and mRNAs for these proteins. All of these components were first believed to be present in the heart and blood vessels; however, it is now known that renin in the circulating blood derived from the kidney is used for the local synthesis of angiotensins. The main emphasis of the review is on the renal RAS because it is believed that the local RAS is most prominent in this organ. The renal RAS is probably involved in the long-rather than short-term regulation of renal vascular resistance and maintenance of normal blood pressure through the regulation of sodium reabsorption.
Authors:
B G Zimmerman; E W Dunham
Related Documents :
1986506 - Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
699246 - Angiotensin converting enzyme inhibition in patients with congestive heart failure.
6989846 - Hypertension associated with hyperparathyroidism is not responsive to angiotensin block...
402166 - The effects of edta and egta on renin secretion.
18685926 - Systematic evaluation of nitric oxide, tetrahydrobiopterin, and anandamide levels in a ...
18360016 - A study of the white-coat phenomenon in patients with primary hypertension.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annual review of pharmacology and toxicology     Volume:  37     ISSN:  0362-1642     ISO Abbreviation:  Annu. Rev. Pharmacol. Toxicol.     Publication Date:  1997  
Date Detail:
Created Date:  1997-07-01     Completed Date:  1997-07-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7607088     Medline TA:  Annu Rev Pharmacol Toxicol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  53-69     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, University of Minnesota, Minneapolis 55455, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / biosynthesis,  blood
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Animals
Blood Pressure / drug effects
Kidney / drug effects,  metabolism,  physiology
Muscle Contraction / drug effects
Muscle, Smooth, Vascular / drug effects,  physiology
Renin / blood
Renin-Angiotensin System / drug effects*,  physiology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 11128-99-7/Angiotensin II; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The toxicology of environmental tobacco smoke.
Next Document:  Structure-based drug design: computational advances.